

## MOLECULAR AND GENOMIC PATHOLOGY SERVICES - ONCOLOGY

All Information Must Be Completed Before Sample Can Be Processed. Please Type or Print.

### PATIENT INFORMATION

Patient Name: \_\_\_\_\_  
Last First MI

Address: \_\_\_\_\_

Home Phone: \_\_\_\_\_

MR# \_\_\_\_\_ Date of Birth \_\_\_\_\_ / \_\_\_\_\_ / \_\_\_\_\_

Gender: ☐ Male ☐ Female

### CLINICAL HISTORY

Clinical History: \_\_\_\_\_

\_\_\_\_\_

ICD-10 Code: \_\_\_\_\_

### SAMPLE/SPECIMEN INFORMATION

Specimen Type:

- ☐ FFPE tissue (paraffin block, or 1 H&E plus 6 unstained slides)\*\*  
☐ Peripheral blood  
☐ Bone marrow

Collection Date/Time: \_\_\_\_\_

Phone # for questions: \_\_\_\_\_

FedEx account number\*: \_\_\_\_\_

\*For tissue block. If not provided, blocks will be returned via regular mail.

**Please ship materials to:**

Cincinnati Children's Hospital Medical Center  
Attn: Molecular and Genomic Pathology Services (MGPS)  
3333 Burnet Avenue, R2.001  
Cincinnati, OH 45229-3039

*Note: Please see test information sheet for acceptable specimen type, collection container, and volume.*

### ORDERING PHYSICIAN INFORMATION

Office/ Practice/ Institution Name: \_\_\_\_\_

Ordering Physician: \_\_\_\_\_

Street Address: \_\_\_\_\_

City: \_\_\_\_\_

State: \_\_\_\_\_ Postal Code: \_\_\_\_\_ Country: \_\_\_\_\_

Phone: \_\_\_\_\_ Fax: \_\_\_\_\_

Email Address: \_\_\_\_\_

### BILLING INFORMATION

#### REFERRING INSTITUTION

Institution: \_\_\_\_\_

Address: \_\_\_\_\_

City/State/Zip: \_\_\_\_\_

Accounts Payable Contact Name: \_\_\_\_\_

Phone: \_\_\_\_\_

Fax: \_\_\_\_\_

Email: \_\_\_\_\_

**\*\*\* Please note, we DO NOT bill the patient or their insurance unless they are transferring care to Cincinnati Children's. \*\*\***

### TEST(S) REQUESTED

\*\*For tests ordered on formalin-fixed, paraffin-embedded tissue, the molecular pathologist or laboratory director will review histologic material for adequacy and appropriate test indication.

**A final or preliminary surgical pathology or cytopathology report must accompany the test requisition.\*\***

#### ☐ HistoTrak

Used for monitoring the disease burden of patients with histiocytosis that harbor a BRAF V600E mutation, during or after therapy. In this setting, it is NOT a diagnostic test. Prior BRAF V600E mutation status should be known before performing the test. In select instances, HistoTrak testing can be used to determine BRAF V600E mutation status on tissue (FFPE) specimens, where the BRAF V600E immunohistochemical finding is equivocal or not available.

#### ☐ CinCSeq Comprehensive Cancer Panel

#### ☐ FLT3-ITD testing (blood and bone marrow only)

#### ☐ Pathologic Consult/Second Opinion

### PHYSICIAN SIGNATURE

Ordering Physician Signature (REQUIRED) \_\_\_\_\_ Date: \_\_\_\_\_ / \_\_\_\_\_ / \_\_\_\_\_